• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Vaxcyte Inc.

    4/28/25 4:03:52 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCVX alert in real time by email
    DEFA14A 1 d901504ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Under § 240.14a-12

    VAXCYTE, INC.

    (Name of Registrant as Specified in its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

    Payment of Filing Fee (Check the appropriate box)

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit requirement by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


                    
                         
       

     

    Your Vote Counts!

          

     

     

     

          LOGO

     

             VAXCYTE, INC.

             825 INDUSTRIAL ROAD

             SUITE 300

             SAN CARLOS, CA 94070

     

     

    VAXCYTE, INC.

     

    2025 Annual Meeting

    Vote by June 11, 2025

    8:59 PM PT / 11:59 PM ET

     

     

       

     

      LOGO               
       

     

     

       

     

     

     

       
       

     

         
     
     
         
     
         

          V70421-P27437

                  
                 

    You invested in VAXCYTE, INC. and it’s time to vote!

    You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 12, 2025.

    Get informed before you vote

    View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 29, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

     

        LOGO

     

       For complete information and to vote, visit  www.ProxyVote.com   
     

           Control #

     

     

    LOGO

     

     

    Smartphone users

     

          LOGO    Vote Virtually at the Meeting*
    Point your camera here and       June 12, 2025
    vote without entering a       8:30 AM PT / 11:30 AM ET
    control number      

    LOGO

         

     

    Virtually at:

          www.virtualshareholdermeeting.com/PCVX2025
         
         
     

    *Please check the meeting materials for any special requirements for meeting attendance.


     Vote at www.ProxyVote.com

     

     

     

     THIS IS NOT A VOTABLE BALLOT

    This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote on these important matters. Before voting, we encourage you to access and review the proxy materials, which contain important information and are available on the Internet or by mail.

     

     

     

       Voting Items            

    Board

    Recommends

     
    1.    Election of Class II Directors        
     
       Nominees would serve until the 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director’s death, resignation or removal.  
     
       Nominees:         LOGO  For
     
       01)    John Furey        
       02)    Jacks Lee        
         03)    Heath Lukatch, Ph.D.              
     
    2.    Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.   LOGO  For
     
    3.    Approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers.   LOGO  For
     
    4.    Approval of the amendment and restatement of the Company’s Amended and Restated Certificate of Incorporation to provide for officer exculpation as permitted by recent amendments to the Delaware General Corporation Law.   LOGO  For

    NOTE: The proxies may vote in their discretion upon any other business that may properly come before the meeting or any adjournment thereof.

       

     

     

     

     

     

    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

     

    V70422-P27437      

    Get the next $PCVX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PCVX

    DatePrice TargetRatingAnalyst
    4/22/2025Overweight
    Cantor Fitzgerald
    12/20/2024$135.00Buy
    Goldman
    12/7/2023$69.00Buy
    Mizuho
    4/18/2023Outperform
    TD Cowen
    1/3/2023$52.00 → $58.00Buy
    Needham
    12/15/2022$66.00Buy
    Guggenheim
    11/17/2022$69.00Buy
    BTIG Research
    12/29/2021$50.00Buy
    Jefferies
    More analyst ratings

    $PCVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

      -- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Complete Booster Data Up to Nine Months Later -- -- Company Expects to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Announced VAX-XL, Third-Generation Pneumococcal Conjugate Vaccine Candidate Desig

      5/7/25 4:01:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

      SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.

      5/1/25 8:00:29 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

      -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu

      3/31/25 7:00:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Financials

    Live finance-specific insights

    See more
    • Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

      -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu

      3/31/25 7:00:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

      SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants. To participate in the conference call, p

      3/30/25 5:00:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

      SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. To participate in the conference call, please dial 800-225-9448 (domestic) or 203-518-9708 (international) and refer to conference ID PCVXQ424. A live webcast

      2/12/25 4:05:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Brandicourt Olivier

      4 - Vaxcyte, Inc. (0001649094) (Issuer)

      5/2/25 4:28:47 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Brandicourt Olivier claimed no ownership of stock in the company (SEC Form 3)

      3 - Vaxcyte, Inc. (0001649094) (Issuer)

      5/2/25 4:27:02 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Dhaliwal Harpreet S. claimed ownership of 36,083 shares (SEC Form 3)

      3 - Vaxcyte, Inc. (0001649094) (Issuer)

      4/25/25 4:13:50 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Vaxcyte

      Cantor Fitzgerald initiated coverage of Vaxcyte with a rating of Overweight

      4/22/25 7:35:12 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Vaxcyte with a new price target

      Goldman initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $135.00

      12/20/24 7:47:04 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho initiated coverage on Vaxcyte with a new price target

      Mizuho initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $69.00

      12/7/23 7:01:04 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Leadership Updates

    Live Leadership Updates

    See more
    • Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

      SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.

      5/1/25 8:00:29 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints John Furey to Board of Directors

      SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Board of Directors. "We are thrilled to welcome John to Vaxcyte's Board of Directors and look forward to benefiting from his wealth of biopharmaceutical and vaccine expertise, including the manufacture, supply and commercialization of pneumococcal conjugate vaccines (PCVs)," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "As we continue to progress our PCV candidates, VAX-24

      7/2/24 8:30:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints Whitney Jones as Chief People Officer

      -- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Whitney Jones as Chief People Officer. Ms. Jones will lead Vaxcyte's human resources strategy and operations, including people and culture, talent acquisition and management, learning and development, total rewards and employee engagement. "At Vaxcyte, we are proud to cultivate a culture that values coll

      1/16/24 4:01:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $PCVX
    SEC Filings

    See more
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/14/24 5:46:11 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/14/24 2:53:06 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/12/24 10:34:18 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.

      SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      5/15/25 4:51:54 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Vaxcyte Inc.

      10-Q - Vaxcyte, Inc. (0001649094) (Filer)

      5/7/25 4:23:38 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vaxcyte, Inc. (0001649094) (Filer)

      5/7/25 4:03:56 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care